---
title: "Korro Bio To Advance KRRO-111 As Potential Treatment For AATD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287089978.md"
description: "Korro Bio Inc. has chosen KRRO-111 as a candidate for clinical development to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting 3.4 million people globally. KRRO-111, a GaINAc-conjugate oligonucleotide, has shown over 90% RNA-editing success in preclinical studies. The company plans to present data on its preclinical validation. KRRO shares are currently trading at $9.32, up 1.86%."
datetime: "2026-05-20T15:20:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287089978.md)
  - [en](https://longbridge.com/en/news/287089978.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287089978.md)
---

# Korro Bio To Advance KRRO-111 As Potential Treatment For AATD

(RTTNews) - Korro Bio Inc. (KRRO), a biopharmaceutical company, has selected KRRO-111 as a development candidate for clinical advancement in the potential treatment of alpha-1 antitrypsin deficiency.

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that causes the depletion of protein in the lungs and liver, leading to pulmonary emphysema and/or hepatic cirrhosis. Affecting nearly 3.4 million people worldwide, the only current FDA-approved treatment for AATD is a once-weekly infusion of human plasma-derived AAT protein called augmentation therapy.

KRRO-111 is a proprietary, GaINAc-conjugate oligonucleotide designed for subcutaneous delivery to liver cells.

In preclinical studies, the drug has demonstrated successful RNA-editing by more than 90% in cells, correcting AAT transcription in liver cells. In mice models, the production of circulating M-AAT protein indicates the potential to improve lung and liver manifestations of the disease.

The company plans to present data on the preclinical validation of KRRO-111 as a candidate in treating AATD.

KRRO is currently trading at $9.32, up 1.86%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [KRRO.US](https://longbridge.com/en/quote/KRRO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)